News
(2)April 2026
BLTE Initiates Rolling NDA Submission for Stargardt Drug tinlarebant
# 📄 What This Document Is 📰 This filing is a Current Report (Form 6-K) released on April 21, 2026. It serves as a major announcement detailing a significant milestone in Belite Bio’s development journey. Essentially, the company is confirming that it has begun the formal process of submitting its
March 2026
BELITE BIO, INC — 6-K Filing
# 🧾 What This Document Is This is a **6-K form**, which is a report foreign companies (like Belite Bio, incorporated in the Cayman Islands) file with the SEC to announce important events. This specific filing is a press release announcing that the company's **full-year 2025 annual report** is now
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.